Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Nanjing Legend Raises $150 Million for Cell Therapies in an A Round/Pre-IPO Financing

publication date: Apr 2, 2020

Nanjing Legend Biotech, a subsidiary of GenScript, raised $150 million in a pre-IPO round from Hudson Bay Capital, J&J Development, Lilly Asia Ventures, Vivo Capital, RA Capital and others. One month ago, GenScript announced it was spinning off Legend so that it can stage an IPO on a US exchange. The $150 million can also be considered an A round, because Legend has built its business on support from GenScript and a $350 million upfront fee that J&J/Janssen paid to partner Legend's CD38 CAR-T candidate in 2017. More details....

Stock Symbols: (HK: 1548) (OTC: GNNSF)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.